Pharsight

Imcivree patents expiration

IMCIVREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(10 years from now)

Imcivree is owned by Rhythm.

Imcivree contains Setmelanotide Acetate.

Imcivree has a total of 3 drug patents out of which 0 drug patents have expired.

Imcivree was authorised for market use on 25 November, 2020.

Imcivree is available in solution;subcutaneous dosage forms.

Drug patent challenges can be filed against Imcivree from 25 November, 2024.

The generics of Imcivree are possible to be released after 04 July, 2034.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-336) Nov 25, 2027
New Chemical Entity Exclusivity(NCE) Nov 25, 2025
Orphan Drug Exclusivity(ODE-402) Jun 16, 2029
New Indication(I-892) Jun 16, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: 25 November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

IMCIVREE family patents

Family Patents